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Abstract
Cytomegalovirus reactivation can be life threatening. However, little evidence on its incidence in solid cancers is available.
Therefore our single center Cytomegalovirus polymerase chain reaction database with altogether 890 CMV positive blood
serum samples of mainly hematological and oncological patients was retrospectively analyzed to examine the occurrence
of Cytomegalovirus reactivation in patients with solid tumors, resulting in 107 patients tested positive for Cytomegalovirus
reactivation. Seventeen patients with solid cancer and a positive CMV-PCR test were identified, of which eight
patients had clinically relevant CMV disease and received prompt antiviral treatment. Five patients fully recovered,
but despite prompt antiviral treatment three patients died. Among these three patients two had significant co-infections
(in one case EBV and in the other case Aspergillus) indicating that that CMV reactivation was at least one factor
contributing to sepsis. The patient with the EBV co-infection was treated in an adjuvant therapy setting for breast
cancer and died due to Cytomegalovirus and Epstein-Barr virus associated pneumonia despite intensive therapy.
The other two patients had progressive disease of an underlying pancreatic cancer at the time of CMV diagnosis.
One patient died due to attendant uncontrollable Aspergillus pneumonia, the other patient most likely died
independent from CMV disease because of massively progressive underlying disease.
Cytomegalovirus reactivation and disease might be underestimated in routine clinical practice. In our retrospective
analysis we show that approximately 50 % of our patients suffering from solid cancers with a positive Cytomegalovirus
polymerase chain reaction also had clinically relevant Cytomegalovirus disease requiring antiviral therapy.
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Background
Cytomegalovirus (CMV) reactivation especially in im-
munocompromised patients may rapidly progress to a
fatal CMV disease associated with significant morbidity
and mortality [1–3]. However only limited data is available
on the role of CMV reactivation/disease in patients with
solid cancers e.g. under chemotherapeutic treatment. In
our clinical experience CMV reactivation is an important
differential diagnosis in the infectiological work up of
these patients. Guidlines on this subject are not jet avail-
able To our knowledge nowadays only a few small case
reports or post-mortem analyses are available: A single
center study that analyzed 107 patients with CMV disease,
including 75 with solid cancer, reported a mortality rate of
61.3 % [4]. In a retrospective post-mortem analysis of 47
cancer patients, with a biopsy-positive gastro intestinal
CMV disease,13 had an underlying solid cancer [5]. Fur-
ther death attributable to CMV was reported in 42 % of a
study cohort that included hematological and solid tumor
manifestations [6]. These data suggest that there exists a
reliable risk of CMV reactivation/disease in solid cancer
patients. We investigated the incidence and impact of
CMV reactivation in solid cancer patients by performing a
retrospective analysis of our single center CMV database.
The database was generated by evaluation of all CMV-
PCR analyses done during the infectiological work up of
our mainly hematological and oncological patients treated
between January 2007 and October 2012. Altogether 890
blood serum samples were collected and analyzed by quali-
tative and quantitative PCR. Positivity in the qualitative
CMV-specific real time PCR assay (Artus CMV PCR kit,
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Qiagen, Hilden, Germany) of serum was defined as CMV
viremia with a cut off of > 20 copies/ml. In case of CMV
positivity indicating clinical relevant CMV infection a tis-
sue specimen was as far as possible depending on the clin-
ical features gained by bronchoscopy (pneumonitis, e.g.) or
endoscopy (gastrointestinal symptoms, e.g. diarrhea).
Retrospective database analysis
CMV – PCR positivity as defined was detected in 107 of
our hematological and oncological patients. Of these 107
patients 17 patients had a solid cancer; the remaining 90
patients had underlying hematological diseases (e.g. Acute
Myeloid Leukemia, Chronic Lymphatic Leukemia and
Non-Hodgkin Lymphoma) and/or HIV infection. In our
further analysis we concentrated on the patients with solid
cancers.
The median age of the patients in the solid cancer cohort
with a positive CMV PCR was 70.6 years (range, 52–93
years). The eight patients who developed clinically relevant
CMV disease were slightly older, with a median age of
71,6 years (range, 63–85 years) and had a higher median
copy number of 6813 copies/ml (range, 476–18,000
copies/ml) compared to 4590 copies/ml (range, 34–18,000
copies/ml) in the whole solid cancer CMV PCR positive
cohort.
At the time of diagnosis 15 of the 17 patients with solid
cancers underwent chemotherapy. Five patients received
chemotherapy in an adjuvant setting. Ten patients were
treated within a palliative setting for metastasized disease
(Most of these patients already underwent multiple courses
of chemotherapy before). One patient was solely treated
with anti-hormonal therapy in a palliative setting, never
receiving any kind of chemotherapy before. One additional
patient in an adjuvant setting did not receive any kind of
chemotherapy at the time of reactivation. Primary tumor
sites and their distribution were as follows: breast cancer in
six patients, pancreatic cancer in three, carcinoma of un-
known origin in three, squamous cell lung cancer in two,
small cell lung cancer in two and esophageal cancer in one
patient.
Co-Infections at the time of CMV-positivity were given
in 9 of 17 patients with Aspergillus in two patients,
Candida in one patient, Pseudomonas aeruginosa in one
patient, Epstein-Barr virus (EBV) in four patients and
Herpes-Simplex virus (HSV) in two patients. During the
detection of CMV positivity, four patients had an absolute
neutrophil count of < 500/μl, nine patients showed ele-
vated C-reactive protein levels (>10 mg/dl) at the time of
CMV PCR positivity detection. Because most patients
were in an advanced disease stage, several comorbidities
and a history of infectious complications during the course
of chemotherapy were observed, as well as hypoalbu-
minemia. Comorbidities in the patient cohort were dis-
tributed as follows: the most common comorbidity was
hypertension in four patients, followed by chronic ob-
structive pulmonary disease in two patients, cerebral in-
sult and diabetes mellitus II in one patient, and nutritive
toxic liver cirrhosis in one patient. Quantitative data on
immunoglobulin (Ig) G status were available in four pa-
tients, one patient showed a decrease to < 400 mg/dl (nor-
mal range: 700–1600 mg/dl).
The median time from cancer diagnosis to overt CMV
disease was 5.6 months (range, 1–24 months) and time
to recovery or death from CMV infection ranged be-
tween 3 and 5 weeks. Table 1 shows the characteristics
of these 17 patients in more detail.
Clinically apparent CMV disease was diagnosed in 8
of 17 patients with CMV-PCR positivity. CMV disease
was considered to be clinically relevant when fever of
unknown origin persisted despite broad antibiotic +/−
antimycotic treatment and CMV-PCR positivity was
given. In these cases, antiviral therapy was promptly
started with intravenous ganciclovir 5 mg/m2 twice a
day. After start of antiviral therapy longitudinal CMV-
PCR quantifications under antiviral treatment were
done. In 5 of 8 patients the CMV copy numbers re-
duced to within normal range under antiviral therapy.
All these five patients survived their infectious compli-
cation. In the remaining three patients the longitudinal
CMV copy numbers after start of therapy could not be
obtained due to fulminante clinical course. Of these
three patients one patient died because of infectious
complications of CMV and attendant EBV reactivation,
one died due to CMV and Aspergillus infection, and
one patient died from massively progressive underlying
disease most likely independent from CMV disease be-
fore getting any specific antiviral therapy. A more de-
tailed description of the three patients who succumbed




The patient was a 65-year-old man with newly diag-
nosed adenocarcinoma of the pancreatic tract with
hepatic, peritoneal and pulmonary metastases. After a
single course of palliative chemotherapy with gemcita-
bine (1000 mg/m2) the patient was hospitalized with
high fever and a poor general health status. Within 2 h
after hospitalization, he developed sepsis with organ
failure before starting any specific therapy. Post-mortem
blood cultures were only positive for CMV with a copy
number of 3409 copies/ml detected by CMV-PCR. No fur-
ther pathogen was detected in the blood cultures.
Case 2
The patient was a 70-year-old woman who had been
receiving adjuvant therapy for triple negative breast
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cancer diagnosed in August 2010. She received three
cycles of epirubicin (60 mg/m2) and cyclophosphamide
(60 mg/m2), as well as two applications of taxotere
(75 mg/m2) with G-CSF prophylaxis. After the second
cycle of paclitaxel, she experienced fever of 38.8 °C. An
intensive clinical work-up including laboratory testing,
chest x-ray, and blood cultures was performed without
gaining any infectiological focus or pathogen except
positivity for CMV and EBV-PCR. Treatment with gan-
ciclovir and specific immunoglobulin was promptly
started. However, the patient’s respiratory status dete-
riorated and she had to be transferred to the intensive
care unit (ICU), where the CMV and EBV pneumonia
was confirmed by bronchoscopy. The patient died
from GI-bleeding 16 days after the CMV and EBV in-
fection became evident.
Case 3
The patient was a 60-year-old woman with metastatic
pancreatic carcinoma who was under palliative ther-
apy with 5-FU, leucovorin, irinotecan and oxaliplatin.
After a single course of chemotherapy, the patient
developed multiple pulmonary infections resulting in
cardiorespiratory insufficiency leading to an ICU ad-
mission. The microbiological work-up resulted in the
detection of Aspergillus, herpes simplex virus (HSV),
EBV and CMV in BAL specimens. Despite intensive
antimicrobial therapy including ganciclovir, the patient
succumbed to uncontrollable Aspergillus pneumonia.
Conclusion
CMV disease is a well-known complication in immuno-
compromised or organ transplanted patients. However, lit-
tle evidence is available regarding the incidence of CMV
disease in patients with solid cancers. In the present single
center retrospective analysis, we showed the clinical impact
of CMV reactivation and viremia in solid tumor patients.
Accumulating data suggests that CMV disease in these pa-
tients is more frequent than previously estimated. Further-
more it has to be pointed out that CMV testing is not
routinely done in clinical practice and that therefore CMV
reactivation or disease may be underreported. Viral load to
be of significance was considered to be above >1000copies/
ml, due to a lack of guidlines. In the current manuscript
the average viral load is > 4000copies /ml.
Our data show that approximately 50 % of patients
with CMV PCR positivity developed clinically relevant
CMV-viremia, requiring specific therapy. The early ad-
ministration of specific antiviral treatment may improve
the outcome of these patients and may avoid unsuccess-
ful antibiotic therapy and prolonged hospitalization. Cli-
nicians should be aware of the broad range of potential
complications of CMV infection in these patients.
We therefore propose the inclusion of routine CMV
screening in solid cancer patients presenting with fever
or unknown origin. Larger studies are necessary to iden-
tify the risk factors of developing CMV disease. The
increase in the number of elderly patients receiving
chemotherapy and the fact that CMV prevalence
Table 1 Patients characteristics
Gender Age Tumor entity TX setting Tumor therapy CMV copies/mL Assay (specimen) Kind of co-infection CMV therapy Outcome
f 59 Breast adjuvant no 235 blood no no alive
m 59 SCLC palliative CTX 132 blood no no alive
f 79 SCLC palliative CTX 34 blood HSV-esophagitis no alive
f 93 Breast palliative anti-hormonal 120 blood no no alive
m 70 SCC adjuvant CTX/RTX 62 blood no no alive
m 52 SCC palliative CTX/RTX 7,650 blood no no alive
f 53 Breast palliative CTX 8,000 blood no no alive
m 76 CUP palliative CTX 129 blood no no alive
f 63 Pancreas palliative CTX 34 blood no no alive
m 65 Pancreas palliative CTX 3,409 blood EBV, candida, pseudomonas no death
m 85 Esophagus palliative CTX 4,500 blood no gancyclovir alive
f 65 Breast/Lung adjuvant CTX 14,000 blood & BAL EBV, HSV gancyclovir alive
m 67 CUP palliative CTX 18,000 blood no gancyclovir alive
f 72 CUP palliative CTX 8434 blood no gancyclovir alive
f 63 Breast adjuvant CTX 476 blood no gancyclovir alive
f 81 Pancreas palliative CTX 6,000 blood Aspergillus, EBV, candida gancyclovir death
f 69 Breast adjuvant CTX 6,810 blood & BAL Aspergillus, EBV gancyclovir death
BAL bronchioloalveolar lavage, CMV cytomegalovirus, CTX chemotherapy, CUP carcinoma of unknown origin, EBV Epstein-Barr virus, HSV herpes-simplex virus, RTX
radiotherapy, SCC squamous cell cancer, SCLC small cell lung cancer
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increases with age suggests that CMV reaction and CMV
disease are treatment complications that will increase in
frequency in the future.
Consent
The current retrospective analysis underwent critical
evaluation by the local ethical committee regarding the
necessity of an informed written consent. Accordingly,
it was concluded that written IC was not needed due to
the retrospective and non-invasive character of the
current analysis. Moreover, none of the patients was
alive at time of evaluation.
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